Speciality: Oncology
Description:
A warm welcome to all the medical professionals in this exciting learning session on managing Ph negative Acute lymphoblastic leukemia in adults.
Acute Lymphoblastic Leukemia (ALL) is a cancer of the blood and bone marrow that progresses rapidly without treatment. It can reoccur after being in remission from previous treatment. It has been noted that refractory ALL did not respond to treatment indicating the previous treatments did not kill enough leukemia cells (blasts) to reach complete remission.
Ph-positive ALL is a special type of ALL in which a genetic mutation is observed in the Philadelphia chromosome. In the case of Ph-negative ALL, genetic disparities are also observed and most importantly in Ph neg ALL there is a disproportionate survival rate among the patients.
Managing Ph neg ALL often becomes difficult, however, the procedures of management of Philadelphia chromosome (Ph)–negative acute lymphoblastic leukemia (ALL) have changed dramatically in recent years leading to a positive vibe for the situation.
Therefore, have overall knowledge regarding the management of Ph negative ALL. Listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
TRK Inhibitor Active in Treatment-Refractory Glioblastoma
2.
Hair Growth After Cancer; 'Global' Early-Onset CRC; Retifanlimab Boosts OS in NSCLC
3.
Omitting Biopsy After Negative MRI Halves Diagnoses of Insignificant Prostate Cancer
4.
Alkem introduces cetuximab under the trade name Cetuxa in India.
5.
A specific drug combination is being tested in a clinical trial for the deadly brain cancer glioblastoma.
1.
Lentigo Maligna Melanoma: Everything You Need To Know about This Skin Cancer
2.
Unlocking the Potential of SCD: A Comprehensive Guide to Diagnosis and Treatment
3.
The Benefits and Side Effects of Vidaza Syndrome
4.
Exploring Innovative Approaches to Esophageal Cancer Treatment
5.
Understanding the Role of CA 19-9 in Cancer Diagnosis and Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC
2.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
3.
Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment
4.
Navigating the Complexities of Ph Negative ALL - Part XV
5.
Navigating the Complexities of Ph Negative ALL - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation